In this last study, one patient with a T-ALL with CDKN2A/CDKN2B deletion and PTEN loss was treated with ribociclib and everolimus, achieving a clinical response with a decrease in the number of blasts but ultimately experiencing the progressing disease. This evidence concerns the gene CDKN2A and acute lymphoblastic leukemia.